Cargando…

Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo

Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verrier, Bernard, Paul, Stéphane, Terrat, Céline, Bastide, Liza, Ensinas, Agathe, Phelip, Capucine, Chanut, Blandine, Bulens-Grassigny, Laura, Jospin, Fabienne, Guillon, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491952/ https://www.ncbi.nlm.nih.gov/pubmed/28713388 http://dx.doi.org/10.3389/fimmu.2017.00770

Ejemplares similares

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

HIV-1 gp41 and TCRα Trans-Membrane Domains Share a Motif Exploited by the HIV Virus to Modulate T-Cell Proliferation
por: Cohen, Tomer, et al.
Publicado: (2010)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses
por: Gutjahr, Alice, et al.
Publicado: (2020)

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein
Publicado: (1993)

An Accurate Confirmation of Human Immunodeficiency Virus Type 1 (HIV-1) and 2 (HIV-2) Infections with a Dot blot assay Using Recombinant p24, gp41, gp120 and gp36 Antigens
por: Ravanshad, Mehrdad, et al.
Publicado: (2004)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
por: Liu, Shujun, et al.
Publicado: (2010)

Cytotoxicity of HIV-gp41 segments expressed inE. coli
por: Yuan, Yuhua, et al.
Publicado: (2004)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
por: Pu, Jing, et al.
Publicado: (2021)

Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?
por: Teixeira, Cátia, et al.
Publicado: (2016)

Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41
por: Blish, Catherine A, et al.
Publicado: (2008)

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination
por: Sharma, SK, et al.
Publicado: (2012)

Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
por: Kahle, Kristen M., et al.
Publicado: (2009)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

Identification of HIV gp41-specific antibodies that mediate killing of infected cells
por: Williams, Katherine L., et al.
Publicado: (2019)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

Effects of the I559P gp41 Change on the Conformation and Function of the Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimer
por: Alsahafi, Nirmin, et al.
Publicado: (2015)

Evaluation of Hematological, Biochemical Profiles and Molecular Detection of Envelope Gene (gp-41) in Human Immunodeficiency Virus (HIV) among Newly Diagnosed Patients
por: Anjum, Asfa, et al.
Publicado: (2022)

Anti-HIV Double Variable Domain Immunoglobulins Binding Both gp41 and gp120 for Targeted Delivery of Immunoconjugates
por: Craig, Ryan B., et al.
Publicado: (2012)

Diversification of Specificity after Maturation of the Antibody Response to the HIV gp41 Epitope ELDKWA
por: White, Henry N., et al.
Publicado: (2012)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

Modulation of Cytokine Release and Gene Expression by the Immunosuppressive Domain of gp41 of HIV-1
por: Denner, Joachim, et al.
Publicado: (2013)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
por: Huang, Jinghe, et al.
Publicado: (2012)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
por: Khasnis, Mukta D., et al.
Publicado: (2016)

Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope
por: Dorgham, Karim, et al.
Publicado: (2019)

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
por: Caillat, Christophe, et al.
Publicado: (2021)

Correction: Effects of the I559P gp41 Change on the Conformation and Function of the Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimer
Publicado: (2015)

The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41
por: Perween, Reshma, et al.
Publicado: (2021)

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
por: Strokappe, Nika M., et al.
Publicado: (2019)

Mutational analysis of HIV-1 gp41 mediated apoptosis and its correlation with fusion/hemifusion
por: Garg, Himanshu, et al.
Publicado: (2006)

Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein
por: Costin, Joshua M, et al.
Publicado: (2007)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
por: Frey, Gary, et al.
Publicado: (2010)

Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay
por: Sardari, Soroush, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pn2j9968r67d7rclfdlf4nqdh4